damgo

DAMGO (DAGO) is an opioid receptor agonist with the ability to affect the locomotive activity in rodents. Possible analgesic agent due to μ-opiod receptor interaction.

DAMGO is a selective peptide agonist of the µ-opioid receptor .

DAMGO TFA (78123-71-4(Free base)) is a potent and selective agonist of the Mu-opioid receptor and an analgesic that stimulates calcium-activated adenylate cyclase-associated cAMP production and induces TGF-beta1 expression at the protein and mRNA levels.

4F 4PP oxalate is a 5-HT2A antagonist.

RR-49 is an innovative difluorinated analogue. This compound demonstrates exceptional pH sensitivity, showing the same efficacy for DAMGO in MOR cAMP assays at pH 6.5 as it does at pH 7.4, but with a 19-fold increase in potency (IC50). It holds significant promise as an analgesic for treating inflammatory pain with a lower potential for abuse.

BNTX (7-Benzylidenenaltrexone) is a selective δ1-opioid receptor antagonist. It competitively counteracts the antisecretory effects of DPDPE, Deltorphin 2, and DAMGO. BNTX is applicable in research focused on antinociceptive effects.

BMS-986122 (BMS 986122) is a positive allosteric modulator of μ-opioid receptors that increases β-arrestin recruitment stimulated by endomorphin 1 in U2OS-OPRM1 human osteosarcoma cells expressing μ-opioid receptors (EC50 = 3 μM).

Acetalin-2, an opioid peptide with the sequence Ac-Arg-Phe-Met-Trp-Met-Arg-NH2, selectively binds to [3 H]DAMGO with a Ki value of 93.3 nM [1].